ERBB2 activating alterations were detected in 5.0% (n = 4,133) of tumors, and 234 of 1,233 (19.0%) patients with ERBB2mut solid tumors received one or more HER2-targeted therapies, including 17 patients with NSCLC enrolled on the DESTINY-Lung01 (NCT03505710) and DESTINY-Lung02 (NCT04644237) clinical trials who received T-DXd (Fig. 5A and B). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.